Betta Pharmaceuticals Co Ltd
SZSE:300558
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/S
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Enterprise Value to Sales (EV/S) ratio compares a company`s total enterprise value to its revenue. It shows how much investors are paying for each dollar of the company`s sales, including both equity and debt.
Valuation Scenarios
If EV/S returns to its 3-Year Average (8), the stock would be worth ¥58.69 (19% upside from current price).
| Scenario | EV/S Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 6.8 | ¥49.52 |
0%
|
| 3-Year Average | 8 | ¥58.69 |
+19%
|
| 5-Year Average | 8.9 | ¥65.41 |
+32%
|
| Industry Average | 3.5 | ¥25.54 |
-48%
|
| Country Average | 3.3 | ¥24.17 |
-51%
|
Forward EV/S
Today’s price vs future revenue
| Today's Enterprise Value | Revenue | Forward EV/S | ||
|---|---|---|---|---|
|
¥19.6B
|
/ |
Oct 2025
¥3.3B
|
= |
|
|
¥19.6B
|
/ |
Dec 2025
¥3.7B
|
= |
|
|
¥19.6B
|
/ |
Dec 2026
¥4.4B
|
= |
|
|
¥19.6B
|
/ |
Dec 2027
¥5.4B
|
= |
|
Forward EV/S shows whether today’s EV/S still looks high or low once future revenue are taken into account.
Peer Comparison
| Market Cap | EV/S | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
B
|
Betta Pharmaceuticals Co Ltd
SZSE:300558
|
20.8B CNY | 6.8 | 68.7 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
804.2B USD | 12.8 | 39 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.4B USD | 5.9 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 4.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
212.4B GBP | 5.1 | 27.5 | |
| CH |
|
Novartis AG
SIX:NOVN
|
220.1B CHF | 5.1 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
274.6B USD | 4.7 | 15 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 108.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 4 | 11.1 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
150.6B USD | 3.2 | 19.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
115.9B USD | 3.1 | 16.4 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.7 |
| Median | 3.3 |
| 70th Percentile | 6.2 |
| Max | 5 034 353.9 |
Other Multiples
Betta Pharmaceuticals Co Ltd
Glance View
Betta Pharmaceuticals Co Ltd., established in 2003, is a dynamic player in China's rapidly evolving pharmaceutical landscape. The company made its mark with a particular focus on the research, development, production, and sale of innovative oncology drugs. Its flagship product, icotinib, a breakthrough therapy for non-small cell lung cancer, propelled Betta Pharmaceuticals into the spotlight, underpinning their pursuit of excellence in targeted cancer treatment. By capitalizing on expertise in small molecule drug discovery, Betta Pharmaceuticals transformed from a bold idea into a critical partner for healthcare providers, offering proprietary products that serve unmet medical needs across China and beyond. Driving its business model is a robust pipeline fueled by an ongoing commitment to research and innovation. Betta Pharmaceuticals thrives on its biodiverse R&D programs which are facilitated through collaborations with world-class research institutes and industry partners. The company's revenues predominantly flow from sales of its own branded oncology drugs, supplemented by royalty streams from licensing agreements. Their approach blends a careful balance of keen scientific inquiry with commercial acumen, as Betta continually reinvests in clinical trials and regulatory approvals to bring new drugs to market. Thus, the company's ability to blend innovation with practical application keeps it well-positioned amid the competitive and ever-evolving global pharmaceutical arena.
